- |||||||||| intranasal carbetocin (LV-101) / Levo Therap
Journal: The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and Psychometric Validation. (Pubmed Central) - Oct 8, 2022 Carbetocin was well tolerated, and the 3.2-mg dose was associated with clinically meaningful improvements in hyperphagia and anxiousness and distress behaviors in participants with PWS. The current body of evidence supports the conclusion that the PADQ measures observable behaviors that are meaningful to patients and their families and provides a valid and reliable method to assess beneficial treatment effects for some of the most challenging behaviors associated with PWS.
- |||||||||| intranasal carbetocin (ACP-101) / Acadia Pharma
Trial completion, Trial completion date: CARE-PWS: Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome (clinicaltrials.gov) - Jul 26, 2022 P3, N=130, Completed, The current body of evidence supports the conclusion that the PADQ measures observable behaviors that are meaningful to patients and their families and provides a valid and reliable method to assess beneficial treatment effects for some of the most challenging behaviors associated with PWS. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jul 2022
|